Straits Times Index
3,192.35 -16.51 (-0.51%) S&P 500
4,234.87 -53.52 (-1.25%) Dow
33,062.65 -370.70 (-1.11%) Nasdaq
13,102.68 -205.09 (-1.54%) Bitcoin USD
27,419.88 -587.06 (-2.10%) CMC Crypto 200
585.88 -4.10 (-0.69%)
LLY Jan 2024 210.000 put
| Previous close | 0.0900 |
| Open | 0.0800 |
| Bid | 0.0400 |
| Ask | 0.4700 |
| Strike | 210.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.0800 - 0.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | 835 |
- Financial Times
Eli Lilly to buy cancer specialist Point for $1.4bn
Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price. The Indianapolis-based pharma group has become the second major drugmaker after Swiss company Novartis to invest in radioligand therapy, which involves molecules delivering radiation at close range to cancerous cells and is more targeted than radiotherapy. Jacob Van Naarden, president of the company’s oncology division Loxo@Lilly, said the acquisition of Point would be the “beginning of our investment in developing multiple meaningful radioligand medicines for hard-to-treat cancers”.
ZacksWhy Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
ZacksLilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection
Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.
